Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 144

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 144
---
 Company Act which invest only in direct U.S. government treasury obligations and/or held as cash or cash items (including in demand deposit accounts). Due to the short -termnature of these investments, we believe there will be no associated material exposure to interest rate risk. Related Party Transactions On June 17, 2024, we issued to our sponsor an aggregate of 22,361,111 ordinary shares for $35,000, or approximately $0.0016 per share. On November6, 2024, the sponsor surrendered and forfeited 12,503,968 ordinary shares to us for no consideration, following which the sponsor holds 9,857,143 founder shares. The purchase price of the founder shares was determined by dividing the amount of cash used to purchase such shares by the number of founder shares issued. Our initial shareholders will own 30% of our issued and outstanding ordinary shares after this offering (not including the private units and the representative shares and assuming they do not purchase any units in this offering). Up to 1,285,714 founder shares are subject to surrender and forfeiture by our initial shareholders depending on the extent to which the underwriters’ over -allotmentoption is exercised. We have entered into an administrative services agreement pursuant to which we have agreed to pay our sponsor or an affiliate $10,000 per month for office space, administrative and support services. Upon completion of our initial business combination or our liquidation, the administrative services agreement will terminate, and we will cease paying these monthly fees. Our audit committee will review and approve all payments that were made by us to our sponsor, directors, officers or our or any of their respective affiliates, which may include reimbursement of any out -of -pocketexpenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no cap or ceiling on the reimbursement of out -of -pocketexpenses incurred by such persons in connection with activities on our behalf. Our sponsor has agreed to loan us up to $1,850,000 under an unsecured promissory note to be used for a portion of the expenses of this offering and to finance transaction costs in connection with an intended initial business combination. As of September 30, 2024, we have borrowed $552,015 under such promissory note. This loan is non -interestbearing and unsecured and will be repayable upon the closing of our initial business combination or upon our dissolution, whichever occurs first. Repayment